StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Up 290.2 %

GLMD stock opened at $15.10 on Friday. Galmed Pharmaceuticals has a 12-month low of $2.73 and a 12-month high of $23.80. The company has a 50 day moving average of $3.83 and a two-hundred day moving average of $4.12. The company has a market cap of $76.18 million, a price-to-earnings ratio of -6.29 and a beta of 0.67.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.